Original Query: ALL
Previous Study | Return to List | Next Study

Effect of Moisturizing Creams on Skin Barrier Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00771121
Recruitment Status : Unknown
Verified October 2008 by ACO Hud Nordic AB.
Recruitment status was:  Recruiting
First Posted : October 13, 2008
Last Update Posted : October 13, 2008
Information provided by:
ACO Hud Nordic AB

Brief Summary:
This study is a randomized, double-blind, placebo-controlled bilateral study on the effect of moisturizing creams on skin barrier function. The hypothesis is that a new active emulsion has a better influence on skin barrier function comapred to its placebo.

Condition or disease Intervention/treatment Phase
Atopic Eczema Drug: urea/lactic acid Drug: Placebo Phase 4

Study Type : Interventional  (Clinical Trial)

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: new emulsion Drug: urea/lactic acid
new emulsion type
Placebo Comparator: new emulsion placebo Drug: Placebo
only emulsion base

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Dry skin barrier disorders such as atopic dermatitis or Malassezia eradicated head and neck dermatitis.
  • Rough or clinically normal skin on the volar aspect of the forearm.
  • Either gender
  • Age between 18 and 65 years
  • Written Informed Consent

Exclusion Criteria:

  • Possible allergy to ingredients in the study medications.
  • Use of any concomitant medication that may interfere with the study related activities or assessment of efficacy.
  • Any patient related factor suggesting potential poor compliance with study procedures (e.g. psychiatric disorders, history of alcohol or substance abuse).
  • Any serious medical condition which, in the opinion of the investigator, may interfere with the evaluation of the results.
  • Pregnancy or breast feeding, or patients who plan to become pregnant during the course of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00771121

Contact: Lena Holm, Dr +46 (0)706-382722

Sophiahemmet Recruiting
Stockholm, Sweden, 114 86
Contact: Lena Holm, Dr    +46 (0)706-382722   
Sophiahemmet Recruiting
Stockholm, Sweden, 114 86
Contact: Lena Holm, Dr    0706-382722   
Principal Investigator: Lena Holm, Dr         
Sponsors and Collaborators
ACO Hud Nordic AB Identifier: NCT00771121     History of Changes
Other Study ID Numbers: ACO2008-CT-01
First Posted: October 13, 2008    Key Record Dates
Last Update Posted: October 13, 2008
Last Verified: October 2008

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases